
Oncology/Haematology Portfolio (approved products & pipeline)



Oncology/Haematology Portfolio



^{*} Approved at least by EMA. Vinorelbine was approved by National Health Authorities (before EU centralized procedure implementation)

^{1.} Commercialized in partnership with Puma Biotechnology

^{2.} Commercialized in partnership with Atara Biotherapeutics

Class

INN /

Compound

Indication or disease

Discovery Preclinical Phase I Phase II Phase III In Registration Approved *

Unresectable or metastatic BRAF V600 - mutant **MELANOMA** Metastatic BRAF V600E - mutant CRC after prior systemic therapy Metastatic BRAF V600E - mutant NSCLC 3 Encorafenib 1 **Targeted** / Binimetinib ² therapy (± other agents) Metastatic BRAF V600E - mutant NSCLC in Chinese population - OCEAN Study Previously untreated metastatic BRAF V600E mutant CRC 4 - ANCHOR CRC Study Previously treated metastatic BRAF V600E mutant CRC in Chinese population -**NAUTICAL Study**

- 1. Encorafenib + Cetuximab is approved for BRAFV600E mutant mCRC, after prior systemic therapy. Encorafenib + binimetinib is approved for unresectable or metastatic BRAF-mutant melanoma, in adult patients.
- 2. Developed and launched in partnership with Array Biophama (partnered with Pfizer since 2020)
- 3. Clinical development under Pfizer sponsorship.
- 4. ANCHOR CRC study status: completed.

^{*} Approved at least by EMA.



INN / Compound	Class	Target and Modality	Indication or disease	Discovery Preclinical Phase I Phase II Phase III
Exarafenib ¹	Targeted therapy	Pan-RAF small molecule Inhibitor	NRAS mutant MELANOMA and other BRAF / NRAS mutant solid tumors	
PFL-721/ STX-721 ²	Targeted therapy	Mutant-selective EGFR-exon20 small molecule inhibitor	NSCLC with EGFR exon 20 insertion mutation	
PFL-241/ STX-241 ²	Targeted therapy	Mutant-selective 4th generation EGFR small molecule inhibitor	NSCLC with EGFR exon 19/21 + C797S mutations	
PFL-002/ VERT-002 ³	Targeted therapy	Anti-cMET antibody degrader	NSCLC / solid tumors with mutations or amplification of MET	
Not-disclosed ⁴	Targeted therapy	Multiple targets	ONCOLOGY	

- 1. Originated by Kinnate Biopharma Inc. Investigational Pan-RAF Inhibitor, Exarafenib, acquired by Pierre Fabre Laboratories
- 2. Co-development in partnership with Scorpion Therapeurics Inc., Boston, USA. The sponsor of these studies could be Pierre Fabre Medical Care or Scorpion Therapeutics Inc.
- 3. Originated by Vertical Bio AG, acquired by Pierre Fabre Laboratories
- 4. Discovery partnership with Vernalis Ltd.